FN1 governs global protein lactylation in acute myocardial infarction: a metabolic-epigenetic axis driving cardiac injury and impeding stem cell repair.

BACKGROUND

Acute myocardial infarction (AMI) triggers metabolic reprogramming, resulting in substantial lactate accumulation. This metabolite drives protein lactylation, a recently recognized post-translational modification that modulates cellular functions. However, the regulatory framework and primary drivers of lactylation in AMI, as well as their impact on myocardial repair, remain poorly defined. The hostile post-infarction microenvironment further limits the therapeutic efficacy of regenerative cell therapies, such as human endometrial mesenchymal stem cells (hEnMSCs). This study aimed to identify a central regulator of protein lactylation during AMI and develop a strategy for microenvironmental reprogramming to enhance stem cell-based interventions.

METHODS

Transcriptomic profiles from AMI patients were integrated with machine learning algorithms and single-cell RNA sequencing to identify core genes. Biological significance was validated using oxygen-glucose deprivation (OGD) cellular models and murine infarction paradigms, employing genetic silencing and lactate administration. The cooperative benefit of modulating the identified target in conjunction with hEnMSC delivery was subsequently assessed.

RESULTS

Our findings establish fibronectin 1 (FN1) as a functional bridge linking metabolic stress to epigenetic modification in AMI. Specifically, we discover that FN1 acts as a critical upstream regulator of global protein lactylation, a mechanism not previously recognized. Simultaneously, we acknowledge that FN1's well-characterized roles in fibrosis, extracellular matrix remodeling, and scar formation may operate as a parallel, independent mechanism contributing to cardiac pathology. By showing that FN1 reduction specifically attenuates lactylation and that lactate supplementation reverses the protective effect, our data pinpoint lactylation as a key downstream effector of FN1's detrimental function in AMI, while its classical functions likely remain active. Targeting this FN1-lactylation axis, particularly through combinatorial FN1 knockdown and stem cell therapy, offers a novel therapeutic strategy beyond conventional anti-fibrotic approaches.

CONCLUSION

This work identifies FN1 as a critical upstream mediator of protein lactylation in AMI. Targeting FN1 not only directly attenuates tissue damage but also reshapes the local microenvironment to empower hEnMSC-mediated repair, offering a theoretical rationale for future preclinical studies combining FN1 targeting with stem cell therapy.